🇺🇸 FDA
Pipeline program

CAP-1002 Allogeneic Cardiosphere-Derived Cells

1002-01

Phase 2 mab terminated

Quick answer

CAP-1002 Allogeneic Cardiosphere-Derived Cells for Myocardial Infarction is a Phase 2 program (mab) at CAPRICOR THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CAPRICOR THERAPEUTICS, INC.
Indication
Myocardial Infarction
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials